Elite Pharmaceuticals (OTCQB: ELTP) has launched a generic version of Requip XL (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets, for the treatment of Parkinson’s disease.
In a press release, the company states that this product is marketed and sold under the Elite Laboratories label.
According to IQVIA, the branded product and its equivalents had total U.S. sales of $10 million for the twelve months ending June 2026.
